T. Rowe Price Associates
DYN icon

T. Rowe Price Associates’s Dyne Therapeutics DYN Stock Holding History

T. Rowe Price Associates’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$42.2M Buy
2,328,373
+4,584
+0.2% +$79K ﹤0.01% 826
2025
Q4 		$45.5M Buy
2,323,789
+925,702
+66% +$17.5M ﹤0.01% 838
2025
Q3 		$17.7M Sell
1,398,087
-985,866
-41% -$11.2M ﹤0.01% 1080
2025
Q2 		$22.7M Buy
2,383,953
+563,538
+31% +$6.2M ﹤0.01% 937
2025
Q1 		$19M Sell
1,820,415
-582,037
-24% -$8.33M ﹤0.01% 969
2024
Q4 		$56.6M Sell
2,402,452
-233,841
-9% -$6.92M 0.01% 720
2024
Q3 		$94.7M Buy
2,636,293
+270,224
+11% +$10.8M 0.01% 582
2024
Q2 		$83.5M Buy
2,366,069
+1,233,977
+109% +$35.9M 0.01% 581
2024
Q1 		$32.1M Buy
1,132,092
+1,118,590
+8,285% +$25.3M ﹤0.01% 844
2023
Q4 		$180K Sell
13,502
-161,885
-92% -$1.58M ﹤0.01% 2578
2023
Q3 		$1.57M Buy
175,387
+164,444
+1,503% +$1.77M ﹤0.01% 1571
2023
Q2 		$124K Sell
10,943
-280,367
-96% -$3.31M ﹤0.01% 2652
2023
Q1 		$3.36M Buy
291,310
+252,232
+645% +$3.28M ﹤0.01% 1290
2022
Q4 		$453K Buy
39,078
+370
+1% +$4.28K ﹤0.01% 2174
2022
Q3 		$493K Buy
38,708
+2,148
+6% +$24.6K ﹤0.01% 2134
2022
Q2 		$251K Buy
36,560
+102
+0.3% +$703 ﹤0.01% 2515
2022
Q1 		$351K Buy
36,458
+700
+2% +$5.96K ﹤0.01% 2485
2021
Q4 		$425K Sell
35,758
-600
-2% -$8.43K ﹤0.01% 2464
2021
Q3 		$590K Buy
+36,358
New +$645K ﹤0.01% 2301
2021
Q1 		– Sell
-484,952
Closed -$10.2M – 2852
2020
Q4 		$10.2M Sell
484,952
-6,519
-1% -$129K ﹤0.01% 1348
2020
Q3 		$9.92M Buy
+491,471
New +$10.8M ﹤0.01% 1302

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

T. Rowe Price Associates's DYN Position: Q1 2026 in Review

T. Rowe Price Associates increased its Dyne Therapeutics (DYN) stake by 0.2% in Q1 2026, buying an estimated $79K and bringing the position to 2,328,373 shares worth $42.2M. The position accounts for ﹤0.01% of the portfolio, ranked #826.

T. Rowe Price Associates first reported a position in DYN in Q3 2020 and has held it in 21 quarters since. The position peaked at $94.7M in Q3 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • T. Rowe Price Associates held 2,328,373 shares of Dyne Therapeutics worth $42.2M as of Q1 2026.
  • T. Rowe Price Associates bought 4,584 Dyne Therapeutics shares in Q1 2026, an estimated $79K.
  • Dyne Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #826 holding.
  • T. Rowe Price Associates first reported a position in Dyne Therapeutics in Q3 2020 and has held it in 21 quarters since.
  • T. Rowe Price Associates's Dyne Therapeutics position peaked at $94.7M in Q3 2024.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.